Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vevorisertib (ARQ 751)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merck (MSD)

Drug class:

pan-AKT inhibitor

Related drugs:

‹

›

PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	ARQ 751 Sensitive: C2 – Inclusion Criteria ARQ 751 Sensitive : C2	ARQ 751 Sensitive: C2 – Inclusion Criteria ARQ 751 Sensitive : C2
AKT1 mutation	Solid Tumor	AKT1 mutation	Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3
PTEN mutation	Solid Tumor	PTEN mutation	Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3
PIK3CA mutation + AKT1 mutation + PTEN mutation	Solid Tumor	PIK3CA mutation + AKT1 mutation + PTEN mutation	Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	palbociclib + ARQ 751 Sensitive: D – Preclinical palbociclib + ARQ 751 Sensitive : D	palbociclib + ARQ 751 Sensitive: D – Preclinical palbociclib + ARQ 751 Sensitive : D